KR20170138437A - 신경질환 치료용 푸마레이트를 정맥투여하는 방법 및 조성물 - Google Patents
신경질환 치료용 푸마레이트를 정맥투여하는 방법 및 조성물 Download PDFInfo
- Publication number
- KR20170138437A KR20170138437A KR1020177029928A KR20177029928A KR20170138437A KR 20170138437 A KR20170138437 A KR 20170138437A KR 1020177029928 A KR1020177029928 A KR 1020177029928A KR 20177029928 A KR20177029928 A KR 20177029928A KR 20170138437 A KR20170138437 A KR 20170138437A
- Authority
- KR
- South Korea
- Prior art keywords
- fumarate
- pharmaceutical composition
- patient
- administered
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title claims abstract description 519
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title claims abstract description 515
- 238000000034 method Methods 0.000 title claims abstract description 451
- 238000011282 treatment Methods 0.000 title claims abstract description 130
- 238000001990 intravenous administration Methods 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000012902 Nervous system disease Diseases 0.000 title abstract description 47
- 208000025966 Neurological disease Diseases 0.000 title abstract description 35
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 84
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 66
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 58
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 51
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims description 384
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical group COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 284
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 279
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 179
- 239000008194 pharmaceutical composition Substances 0.000 claims description 179
- 208000035475 disorder Diseases 0.000 claims description 109
- 150000003839 salts Chemical class 0.000 claims description 93
- 239000004480 active ingredient Substances 0.000 claims description 90
- 201000010099 disease Diseases 0.000 claims description 70
- -1 sulfobutyl ether betacyclodextrins Chemical class 0.000 claims description 69
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 54
- 229940002612 prodrug Drugs 0.000 claims description 54
- 239000000651 prodrug Substances 0.000 claims description 54
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 52
- 229940005650 monomethyl fumarate Drugs 0.000 claims description 52
- 229920000858 Cyclodextrin Polymers 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 230000000750 progressive effect Effects 0.000 claims description 25
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 22
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 22
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 21
- 229960004853 betadex Drugs 0.000 claims description 21
- 239000001116 FEMA 4028 Substances 0.000 claims description 20
- 230000009885 systemic effect Effects 0.000 claims description 19
- 206010020751 Hypersensitivity Diseases 0.000 claims description 17
- 229960005027 natalizumab Drugs 0.000 claims description 16
- 238000011285 therapeutic regimen Methods 0.000 claims description 16
- 230000001010 compromised effect Effects 0.000 claims description 15
- 238000002651 drug therapy Methods 0.000 claims description 15
- 229940124622 immune-modulator drug Drugs 0.000 claims description 15
- 230000001506 immunosuppresive effect Effects 0.000 claims description 15
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 15
- 210000000987 immune system Anatomy 0.000 claims description 14
- 239000000644 isotonic solution Substances 0.000 claims description 14
- 239000006070 nanosuspension Substances 0.000 claims description 13
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 10
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 10
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 10
- 230000000306 recurrent effect Effects 0.000 claims description 10
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 5
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 5
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 2
- 201000002364 leukopenia Diseases 0.000 claims 6
- 231100001022 leukopenia Toxicity 0.000 claims 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 abstract description 105
- 125000000217 alkyl group Chemical group 0.000 description 217
- 229910052739 hydrogen Inorganic materials 0.000 description 126
- 239000001257 hydrogen Substances 0.000 description 125
- 238000012360 testing method Methods 0.000 description 100
- 230000006735 deficit Effects 0.000 description 97
- 230000006378 damage Effects 0.000 description 93
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 86
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 83
- 125000003118 aryl group Chemical group 0.000 description 54
- 230000006872 improvement Effects 0.000 description 53
- 230000006870 function Effects 0.000 description 52
- 125000005842 heteroatom Chemical group 0.000 description 45
- 229910052757 nitrogen Inorganic materials 0.000 description 43
- 125000001072 heteroaryl group Chemical group 0.000 description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 40
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 40
- 206010012289 Dementia Diseases 0.000 description 37
- 210000004556 brain Anatomy 0.000 description 37
- 150000002431 hydrogen Chemical class 0.000 description 37
- 208000010877 cognitive disease Diseases 0.000 description 34
- 229910052805 deuterium Inorganic materials 0.000 description 32
- 230000033001 locomotion Effects 0.000 description 31
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 29
- 230000009184 walking Effects 0.000 description 29
- 230000005021 gait Effects 0.000 description 27
- 229910052760 oxygen Inorganic materials 0.000 description 27
- 208000016285 Movement disease Diseases 0.000 description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 26
- 208000024891 symptom Diseases 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 25
- 229910052717 sulfur Inorganic materials 0.000 description 25
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 24
- 230000001771 impaired effect Effects 0.000 description 24
- 208000028698 Cognitive impairment Diseases 0.000 description 23
- 125000004432 carbon atom Chemical group C* 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 210000003414 extremity Anatomy 0.000 description 23
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 22
- 230000015654 memory Effects 0.000 description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 21
- 125000000623 heterocyclic group Chemical group 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 19
- 238000005259 measurement Methods 0.000 description 18
- 210000003205 muscle Anatomy 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 208000011580 syndromic disease Diseases 0.000 description 17
- 230000006399 behavior Effects 0.000 description 16
- 101150075804 nqo1 gene Proteins 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 230000002354 daily effect Effects 0.000 description 15
- 229910052736 halogen Inorganic materials 0.000 description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 15
- 125000003710 aryl alkyl group Chemical group 0.000 description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 210000001364 upper extremity Anatomy 0.000 description 14
- 208000019505 Deglutition disease Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 150000001721 carbon Chemical group 0.000 description 13
- 150000002367 halogens Chemical class 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 12
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 12
- 101710088194 Dehydrogenase Proteins 0.000 description 12
- 101150005894 GCLC gene Proteins 0.000 description 12
- 206010017577 Gait disturbance Diseases 0.000 description 12
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 12
- 101150044653 HMOX1 gene Proteins 0.000 description 12
- 101001034527 Homo sapiens Glutamate-cysteine ligase catalytic subunit Proteins 0.000 description 12
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 12
- 238000000540 analysis of variance Methods 0.000 description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 238000012423 maintenance Methods 0.000 description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 238000012552 review Methods 0.000 description 11
- 230000000007 visual effect Effects 0.000 description 11
- 206010003591 Ataxia Diseases 0.000 description 10
- 208000010428 Muscle Weakness Diseases 0.000 description 10
- 206010028372 Muscular weakness Diseases 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 125000002837 carbocyclic group Chemical group 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 238000007726 management method Methods 0.000 description 10
- 230000003340 mental effect Effects 0.000 description 10
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 125000003386 piperidinyl group Chemical group 0.000 description 10
- 208000020016 psychiatric disease Diseases 0.000 description 10
- 230000009747 swallowing Effects 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 210000004885 white matter Anatomy 0.000 description 10
- 208000012661 Dyskinesia Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000012879 PET imaging Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 230000001055 chewing effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 210000003811 finger Anatomy 0.000 description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 9
- 230000008449 language Effects 0.000 description 9
- 230000011514 reflex Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000037230 mobility Effects 0.000 description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 7
- 208000014644 Brain disease Diseases 0.000 description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
- 208000032274 Encephalopathy Diseases 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 230000003920 cognitive function Effects 0.000 description 7
- 239000012084 conversion product Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000007659 motor function Effects 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 208000027765 speech disease Diseases 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 206010008748 Chorea Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 102000016173 Oxidative stress-induced growth inhibitor 1 Human genes 0.000 description 6
- 108050004650 Oxidative stress-induced growth inhibitor 1 Proteins 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 208000012601 choreatic disease Diseases 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 239000003966 growth inhibitor Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 208000012639 Balance disease Diseases 0.000 description 5
- 208000004929 Facial Paralysis Diseases 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 5
- 229910005965 SO 2 Inorganic materials 0.000 description 5
- 206010044565 Tremor Diseases 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 229910052788 barium Inorganic materials 0.000 description 5
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 150000003278 haem Chemical class 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 210000002161 motor neuron Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 230000001144 postural effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000009897 systematic effect Effects 0.000 description 5
- 230000004382 visual function Effects 0.000 description 5
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 102000016680 Dioxygenases Human genes 0.000 description 4
- 108010028143 Dioxygenases Proteins 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 208000019430 Motor disease Diseases 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000003930 cognitive ability Effects 0.000 description 4
- 238000011461 current therapy Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- 241000282461 Canis lupus Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical group CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 101150074234 TXNRD1 gene Proteins 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 208000018839 Wilson disease Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000001975 deuterium Chemical group 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000013439 planning Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 229960005333 tetrabenazine Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 2
- AZEGXXPEUOGWGG-SNAWJCMRSA-N (E)-4-(3-ethoxycarbonyloxypropoxy)-4-oxobut-2-enoic acid Chemical compound CCOC(=O)OCCCOC(=O)/C=C/C(=O)O AZEGXXPEUOGWGG-SNAWJCMRSA-N 0.000 description 2
- AYAUWVRAUCDBFR-ONEGZZNKSA-N (e)-4-oxo-4-propoxybut-2-enoic acid Chemical compound CCCOC(=O)\C=C\C(O)=O AYAUWVRAUCDBFR-ONEGZZNKSA-N 0.000 description 2
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 2
- URJPHBCJYCQTKQ-NSCUHMNNSA-N 1-o-methyl 4-o-(2-morpholin-4-yl-2-oxoethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)N1CCOCC1 URJPHBCJYCQTKQ-NSCUHMNNSA-N 0.000 description 2
- YNDLGWWCCXRXQP-NSCUHMNNSA-N 1-o-methyl 4-o-(2-oxo-2-piperazin-1-ylethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)N1CCNCC1 YNDLGWWCCXRXQP-NSCUHMNNSA-N 0.000 description 2
- NUMOPPOEPGJACY-SNAWJCMRSA-N 1-o-methyl 4-o-(2-propan-2-yloxycarbonyloxyethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCOC(=O)OC(C)C NUMOPPOEPGJACY-SNAWJCMRSA-N 0.000 description 2
- HXPUJILWUFUJFD-SNAWJCMRSA-N 1-o-methyl 4-o-[2-(2-methylpropanoyloxy)ethyl] (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCOC(=O)C(C)C HXPUJILWUFUJFD-SNAWJCMRSA-N 0.000 description 2
- MAGHQNDMEULLBK-AATRIKPKSA-N 4-O-(dimethylcarbamoyl) 1-O-ethyl (E)-but-2-enedioate Chemical compound C(\C=C\C(=O)OCC)(=O)OC(N(C)C)=O MAGHQNDMEULLBK-AATRIKPKSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- NVRTZTKFMJETFX-MDZDMXLPSA-N 4-o-(1-benzoyloxy-2-methylpropyl) 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OC(C(C)C)OC(=O)C1=CC=CC=C1 NVRTZTKFMJETFX-MDZDMXLPSA-N 0.000 description 2
- QIJLQYHKDKHWOG-BQYQJAHWSA-N 4-o-(2-benzoyloxyethyl) 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCOC(=O)C1=CC=CC=C1 QIJLQYHKDKHWOG-BQYQJAHWSA-N 0.000 description 2
- OUPDOPULPSPHAA-AATRIKPKSA-N 4-o-[2-(butylamino)-2-oxoethyl] 1-o-methyl (e)-but-2-enedioate Chemical compound CCCCNC(=O)COC(=O)\C=C\C(=O)OC OUPDOPULPSPHAA-AATRIKPKSA-N 0.000 description 2
- AKUGRXRLHCCENI-VOTSOKGWSA-N 4-o-[2-(diethylamino)-2-oxoethyl] 1-o-methyl (e)-but-2-enedioate Chemical compound CCN(CC)C(=O)COC(=O)\C=C\C(=O)OC AKUGRXRLHCCENI-VOTSOKGWSA-N 0.000 description 2
- DNFZKNPDVJWXPG-SNAWJCMRSA-N 4-o-[2-[methoxy(methyl)amino]-2-oxoethyl] 1-o-methyl (e)-but-2-enedioate Chemical compound CON(C)C(=O)COC(=O)\C=C\C(=O)OC DNFZKNPDVJWXPG-SNAWJCMRSA-N 0.000 description 2
- FPIBPYOPUOALEG-MDZDMXLPSA-N 4-o-[4-(cyclohexanecarbonyloxy)butyl] 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCCCOC(=O)C1CCCCC1 FPIBPYOPUOALEG-MDZDMXLPSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- QRJLNZSFGRNYPE-CMDGGOBGSA-N C(\C=C\C(=O)OCCC)(=O)OOC(=O)OC1CCCCC1 Chemical compound C(\C=C\C(=O)OCCC)(=O)OOC(=O)OC1CCCCC1 QRJLNZSFGRNYPE-CMDGGOBGSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010049816 Muscle tightness Diseases 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000011831 SOD1-G93A transgenic mouse Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000000617 arm Anatomy 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Chemical class 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000006998 cognitive state Effects 0.000 description 2
- 230000036992 cognitive tasks Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008921 facial expression Effects 0.000 description 2
- 230000005057 finger movement Effects 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 206010020745 hyperreflexia Diseases 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 230000005032 impulse control Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 208000012866 low blood pressure Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000009023 proprioceptive sensation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000037152 sensory function Effects 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229940121136 tecfidera Drugs 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229910052725 zinc Chemical class 0.000 description 2
- 239000011701 zinc Chemical class 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YSJCXWMBCHDRSE-AIYRYJHASA-N (2s)-2-amino-3-[2-[(e)-4-methoxy-4-oxobut-2-enoyl]oxyethoxycarbonyloxy]propanoic acid Chemical compound COC(=O)\C=C\C(=O)OCCOC(=O)OC[C@H](N)C(O)=O YSJCXWMBCHDRSE-AIYRYJHASA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NKHAVTQWNUWKEO-SMQGVBCRSA-N (e)-4-oxo-4-(trideuteriomethoxy)but-2-enoic acid Chemical compound [2H]C([2H])([2H])OC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-SMQGVBCRSA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- KFRXIVFVFSTXDG-SNAWJCMRSA-N 1-O-ethyl 4-O-[(3-methoxy-3-oxopropyl)carbamoyl] (E)-but-2-enedioate Chemical compound C(\C=C\C(=O)OCC)(=O)OC(NCCC(=O)OC)=O KFRXIVFVFSTXDG-SNAWJCMRSA-N 0.000 description 1
- CAZMXUNUYPZDQR-BQYQJAHWSA-N 1-O-ethyl 4-O-[methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]carbamoyl] (E)-but-2-enedioate Chemical compound C(\C=C\C(=O)OCC)(=O)OC(N(C)CC(=O)OC(C)(C)C)=O CAZMXUNUYPZDQR-BQYQJAHWSA-N 0.000 description 1
- QZUPVNFKOJRJIV-ONEGZZNKSA-N 1-o-methyl 4-o-(1-morpholin-4-yl-1-oxopropan-2-yl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OC(C)C(=O)N1CCOCC1 QZUPVNFKOJRJIV-ONEGZZNKSA-N 0.000 description 1
- QUHFFMRIJHPQQO-NSCUHMNNSA-N 1-o-methyl 4-o-(2-morpholin-4-ylethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCN1CCOCC1 QUHFFMRIJHPQQO-NSCUHMNNSA-N 0.000 description 1
- PRMNHBZFVYAGGY-ONEGZZNKSA-N 1-o-methyl 4-o-(3-morpholin-4-ylpropyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCCN1CCOCC1 PRMNHBZFVYAGGY-ONEGZZNKSA-N 0.000 description 1
- VHYQFUXOHDWOPQ-SNAWJCMRSA-N 1-o-methyl 4-o-(4-morpholin-4-ylbutyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCCCN1CCOCC1 VHYQFUXOHDWOPQ-SNAWJCMRSA-N 0.000 description 1
- OLSWMZAVJQIFBT-AATRIKPKSA-N 1-o-methyl 4-o-(5-morpholin-4-ylpentyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCCCCN1CCOCC1 OLSWMZAVJQIFBT-AATRIKPKSA-N 0.000 description 1
- JYAWNLQXNDOJQX-VOTSOKGWSA-N 1-o-methyl 4-o-(6-morpholin-4-ylhexyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCCCCCN1CCOCC1 JYAWNLQXNDOJQX-VOTSOKGWSA-N 0.000 description 1
- JMJLMVYJKPMZOF-NSCUHMNNSA-N 1-o-methyl 4-o-(trihydroxysilylmethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OC[Si](O)(O)O JMJLMVYJKPMZOF-NSCUHMNNSA-N 0.000 description 1
- JETSOFMWNXQIQA-AATRIKPKSA-N 1-o-methyl 4-o-(trimethoxysilylmethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OC[Si](OC)(OC)OC JETSOFMWNXQIQA-AATRIKPKSA-N 0.000 description 1
- QZUPVNFKOJRJIV-NWALNABHSA-N 1-o-methyl 4-o-[(2s)-1-morpholin-4-yl-1-oxopropan-2-yl] (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)O[C@@H](C)C(=O)N1CCOCC1 QZUPVNFKOJRJIV-NWALNABHSA-N 0.000 description 1
- AHHOEQGJEPBTLF-ONEGZZNKSA-N 1-o-methyl 4-o-[2-(4-methylpiperazin-1-yl)-2-oxoethyl] (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)N1CCN(C)CC1 AHHOEQGJEPBTLF-ONEGZZNKSA-N 0.000 description 1
- PVNJKDKOJORVHB-AEZGRPFRSA-N 1-o-methyl 4-o-[2-[(2s)-2-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-1-yl]-2-oxoethyl] (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)N1CCC[C@H]1C(=O)OC(C)(C)C PVNJKDKOJORVHB-AEZGRPFRSA-N 0.000 description 1
- PIPVOAQWMUIOGV-AATRIKPKSA-N 1-o-methyl 4-o-[2-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-2-oxoethyl] (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)NCC(=O)OC(C)(C)C PIPVOAQWMUIOGV-AATRIKPKSA-N 0.000 description 1
- JQNVWNYYKQTVEH-SNAWJCMRSA-N 1-o-methyl 4-o-[2-oxo-2-(propylcarbamoylamino)ethyl] (e)-but-2-enedioate Chemical compound CCCNC(=O)NC(=O)COC(=O)\C=C\C(=O)OC JQNVWNYYKQTVEH-SNAWJCMRSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical group [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BSSVVSMEAYBMMA-FLOXNTQESA-N 4-o-[(2s)-1-(diethylamino)-1-oxopropan-2-yl] 1-o-methyl (e)-but-2-enedioate Chemical compound CCN(CC)C(=O)[C@H](C)OC(=O)\C=C\C(=O)OC BSSVVSMEAYBMMA-FLOXNTQESA-N 0.000 description 1
- ACRPDRSGQDOEHR-ONEGZZNKSA-N 4-o-[2-(4-acetylpiperazin-1-yl)-2-oxoethyl] 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)N1CCN(C(C)=O)CC1 ACRPDRSGQDOEHR-ONEGZZNKSA-N 0.000 description 1
- KZCQLFYHSPNDFM-BQYQJAHWSA-N 4-o-[2-(4-benzylpiperazin-1-yl)-2-oxoethyl] 1-o-methyl (e)-but-2-enedioate Chemical compound C1CN(C(=O)COC(=O)/C=C/C(=O)OC)CCN1CC1=CC=CC=C1 KZCQLFYHSPNDFM-BQYQJAHWSA-N 0.000 description 1
- TUXXHBPAFNROPA-BQYQJAHWSA-N 4-o-[2-(benzylamino)-2-oxoethyl] 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)NCC1=CC=CC=C1 TUXXHBPAFNROPA-BQYQJAHWSA-N 0.000 description 1
- CRLXDCQHMBLGKY-MDZDMXLPSA-N 4-o-[2-[benzyl-(2-ethoxy-2-oxoethyl)amino]-2-oxoethyl] 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)/C=C/C(=O)OCC(=O)N(CC(=O)OCC)CC1=CC=CC=C1 CRLXDCQHMBLGKY-MDZDMXLPSA-N 0.000 description 1
- KDOXEUDXHVYSAE-MDZDMXLPSA-N 4-o-[3-[benzyl-(2-ethoxy-2-oxoethyl)amino]-3-oxopropyl] 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)/C=C/C(=O)OCCC(=O)N(CC(=O)OCC)CC1=CC=CC=C1 KDOXEUDXHVYSAE-MDZDMXLPSA-N 0.000 description 1
- LMAYDNVIKBCSLP-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NCCC2=N1 LMAYDNVIKBCSLP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- XJYUOUYVWPPUGE-AATRIKPKSA-N C(\C=C\C(=O)OCCC)(=O)OC(N(C)C)=O Chemical compound C(\C=C\C(=O)OCCC)(=O)OC(N(C)C)=O XJYUOUYVWPPUGE-AATRIKPKSA-N 0.000 description 1
- XADACFMGZVCFOL-VOTSOKGWSA-N C(\C=C\C(=O)OCCC)(=O)OC(N(C)CC(=O)OCC)=O Chemical compound C(\C=C\C(=O)OCCC)(=O)OC(N(C)CC(=O)OCC)=O XADACFMGZVCFOL-VOTSOKGWSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
- 235000008474 Cardamine pratensis Nutrition 0.000 description 1
- 240000000606 Cardamine pratensis Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101150043003 Htt gene Proteins 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000025069 Juvenile Huntington disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010057333 Micrographia Diseases 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 206010030312 On and off phenomenon Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010034720 Personality change due to a general medical condition Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000025535 REM sleep behavior disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010071299 Slow speech Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 150000001542 azirines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 231100000727 exposure assessment Toxicity 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000000133 gait apraxia Diseases 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030309 inherited neurodegenerative disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000023515 periodic limb movement disease Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 150000003218 pyrazolidines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- IWDANOJGJIFBEL-UHFFFAOYSA-N spiro[3.4]octane Chemical compound C1CCC21CCCC2 IWDANOJGJIFBEL-UHFFFAOYSA-N 0.000 description 1
- RIGIMRKXSDBOSR-UHFFFAOYSA-N spiro[4.5]deca-3,9-diene Chemical compound C1=CCCC11C=CCCC1 RIGIMRKXSDBOSR-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000012030 stroop test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940025158 xenazine Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136431P | 2015-03-20 | 2015-03-20 | |
| US62/136,431 | 2015-03-20 | ||
| PCT/US2016/023021 WO2016153957A2 (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170138437A true KR20170138437A (ko) | 2017-12-15 |
Family
ID=55702079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177029928A Abandoned KR20170138437A (ko) | 2015-03-20 | 2016-03-18 | 신경질환 치료용 푸마레이트를 정맥투여하는 방법 및 조성물 |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202116297A (zh) * | 2019-07-03 | 2021-05-01 | 西班牙商布爾奴爾法碼有限公司 | 組合療法之方法、組成物與套組 |
| TW202131914A (zh) | 2019-10-30 | 2021-09-01 | 西班牙商布爾奴爾法碼有限公司 | 用於神經疾病或病狀的治療之新治療方案 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DK1663197T3 (da) * | 2003-09-09 | 2008-01-07 | Fumapharm Ag | Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| SI1799196T1 (sl) * | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| EP2653873B8 (en) * | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| HUE032251T2 (en) * | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| MX2011001341A (es) | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| EP3318249A1 (en) | 2009-04-29 | 2018-05-09 | Biogen MA Inc. | Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis |
| DK2533634T3 (en) | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
| JP5072128B2 (ja) * | 2011-03-31 | 2012-11-14 | 株式会社ワコール | カップ部を有する衣類 |
| US20140308244A1 (en) | 2011-08-08 | 2014-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Combination Therapy for Treatment of Inflammatory Demyelinating Disease |
| EP2791181A4 (en) * | 2011-12-16 | 2015-08-05 | Biogen Ma Inc | SILICONE-CONTAINING FUMIC ACID ESTERS |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CA2862885C (en) | 2012-02-07 | 2020-06-02 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| US20140057918A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
| AR094277A1 (es) | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| EP3243511B1 (en) | 2012-12-21 | 2019-03-20 | ratiopharm GmbH | Prodrugs of monomethylfumarate (mmf) |
| CN105163730B (zh) | 2013-01-08 | 2018-10-30 | 帕萨罗杰卡有限公司 | 用于治疗脱髓鞘疾病的方法和组合物 |
| US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US20150079180A1 (en) * | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
-
2016
- 2016-03-17 MA MA041785A patent/MA41785A/fr unknown
- 2016-03-18 JP JP2017549232A patent/JP2018508559A/ja not_active Withdrawn
- 2016-03-18 AR ARP160100749A patent/AR104029A1/es unknown
- 2016-03-18 KR KR1020177029928A patent/KR20170138437A/ko not_active Abandoned
- 2016-03-18 US US15/559,265 patent/US20180289655A1/en not_active Abandoned
- 2016-03-18 MX MX2017012239A patent/MX2017012239A/es unknown
- 2016-03-18 EA EA201792076A patent/EA201792076A1/ru unknown
- 2016-03-18 AU AU2016235743A patent/AU2016235743A1/en not_active Withdrawn
- 2016-03-18 EP EP16715662.9A patent/EP3270895A2/en not_active Withdrawn
- 2016-03-18 HK HK18104073.2A patent/HK1244680A1/zh unknown
- 2016-03-18 CN CN201680028617.1A patent/CN107666905A/zh not_active Withdrawn
- 2016-03-18 CA CA2979544A patent/CA2979544A1/en not_active Abandoned
- 2016-03-18 TW TW105108578A patent/TW201642847A/zh unknown
- 2016-03-18 WO PCT/US2016/023021 patent/WO2016153957A2/en not_active Ceased
-
2017
- 2017-09-18 IL IL254576A patent/IL254576A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107666905A (zh) | 2018-02-06 |
| AR104029A1 (es) | 2017-06-21 |
| IL254576A0 (en) | 2017-11-30 |
| CA2979544A1 (en) | 2016-09-29 |
| US20180289655A1 (en) | 2018-10-11 |
| EP3270895A2 (en) | 2018-01-24 |
| EA201792076A1 (ru) | 2018-04-30 |
| MX2017012239A (es) | 2018-06-27 |
| MA41785A (fr) | 2018-01-23 |
| JP2018508559A (ja) | 2018-03-29 |
| WO2016153957A3 (en) | 2016-11-10 |
| TW201642847A (zh) | 2016-12-16 |
| WO2016153957A2 (en) | 2016-09-29 |
| HK1244680A1 (zh) | 2018-08-17 |
| AU2016235743A1 (en) | 2017-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7819094B2 (ja) | ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法 | |
| JP2018516906A (ja) | レベチラセタムの持続放出性医薬組成物 | |
| KR20220110251A (ko) | 신경변성 질환과 연관된 인지 장애를 치료하는 방법 | |
| TW202345795A (zh) | 純質形式之結晶型阿替卡普蘭 | |
| JP2026031955A (ja) | 自閉症スペクトラム障害の症状を治療する方法 | |
| CN115175911A (zh) | 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法 | |
| CA3189243A1 (en) | Compositions and methods for improving neurological diseases and disorders | |
| EP4297739A1 (en) | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy | |
| US20180289655A1 (en) | Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases | |
| JP6808154B2 (ja) | アダマンタン誘導体およびその使用 | |
| EP4373510A1 (en) | Methods of treating parkinson's disease and/or lewy body disease or disorder(s) | |
| US12496296B2 (en) | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases | |
| US20230414588A1 (en) | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) | |
| JPWO2019026994A1 (ja) | アダマンチルメチルアミン誘導体およびその医薬としての使用 | |
| US12616667B2 (en) | Compositions and methods for improving neurological diseases and disorders | |
| JP6738797B2 (ja) | レット症候群治療薬 | |
| TW202027752A (zh) | 使用ccr-3抑制劑治療老化相關損傷之方法及組合物 | |
| WO2012040444A2 (en) | Treatment of patients with incipient alzheimer's disease | |
| WO2024137506A1 (en) | Compositions and methods for improving neurological diseases and disorders | |
| WO2024137478A1 (en) | Methods for treating various conditions and indications with agonists and antagonists | |
| RU2572706C1 (ru) | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция | |
| HK40080588A (en) | Methods of treating the symptoms of autism spectrum disorder | |
| HK1252154B (en) | Extended release pharmaceutical compositions of levetiracetam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20171017 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1902 | Submission of document of abandonment before decision of registration | ||
| SUBM | Surrender of laid-open application requested |